Is ITGR a buy according to AI stock analysis?

ITGR AI stock analysis does not label Integer Holdings as a simple buy or sell. The business has a defensible CDMO niche with regulatory barriers and recurring revenue, but the stock carries balance sheet leverage and modest profit margins. Buyers should assess their own risk tolerance, debt tolerance, and required return before deciding.

What is the ITGR AI stock forecast?

The ITGR AI stock forecast uses scenarios, not a guaranteed target. Around the $94.57 cutoff price, the bullish scenario is roughly $135 to $175, the base scenario is roughly $90 to $115, and the bearish scenario is roughly $55 to $80, depending on revenue growth, margin execution, debt reduction, and valuation multiples.

What technical levels matter for ITGR?

The key ITGR technical levels are the $98 to $102 near-resistance zone, the $84 to $88 near-support zone, and the $95 to $100 200-day moving average area. The stock must reclaim the 200-day moving average to confirm a sustained recovery trend.

Can AI predict ITGR stock price?

No, AI cannot reliably predict stock prices. AI can organize financial filings, market data, valuation math, technical levels, and risk scenarios, but ITGR can still move sharply after earnings, customer contract announcements, medtech conference presentations, or macro events affecting medical procedure volumes.

How should I use this ITGR AI trading strategy?

Use this ITGR AI trading strategy as a research checklist, not a personal instruction. Confirm live price, volume, moving averages, earnings timing, position size, stop level, and portfolio risk before making any trade.

What is the biggest risk in Integer stock analysis?

The biggest risk in Integer stock analysis is that balance sheet leverage amplifies downside during a cyclical slowdown in medical procedures. With debt-to-equity at 81% and limited cash reserves, the company has less financial flexibility than many medtech peers.

Integer Holdings Corporation research snapshot

ITGR AI Stock Analysis

ITGR AI stock analysis currently reads Integer Holdings Corporation as a specialized medical device contract development and manufacturing organization (CDMO) with competitive advantages in implantable component manufacturing, cardiac rhythm management, and neuromodulation. The analysis does not represent a certain price prediction. At the July 12, 2026 cutoff, the latest verified close was $94.57, market capitalization was about $3.21 billion, and the stock traded near 23.5x trailing earnings with a forward P/E near 20x, reflecting moderate expectations for organic growth, margin expansion, and debt reduction. The main question is whether Integer can sustain revenue growth in the mid-to-high single digits, improve profitability, and reduce leverage in a steady medical procedure volume environment. This is informational research and not investment advice.

Current price

$94.57

Market cap

$3.21 billion

AI score

65 / 100

Rating

Solid business niche, elevated leverage, attractive valuation

Trend status

Recovering from 52-week low, below prior highs

Data cutoff (updated weekly)

July 12, 2026

Informational use only. This page is not investment advice.

Research quality check

information Richness: B-level information richness. Integer has long SEC filing history and active analyst coverage from healthcare-focused firms, but it is less covered than large-cap medtech peers. Some financial details required estimation from available data sources.
bias Check: The main AI bias risk is moderate-data anchoring. Because Integer is a B2B manufacturer rather than a consumer brand, public visibility is lower, but the financial filings and customer relationships are reported regularly. The analysis distinguishes filing-backed facts from scenario judgments.
ai Confidence: Medium-high data confidence
investment Certainty: Medium-low. Integer operates in a defensible niche with switching costs, but the balance sheet carries meaningful debt, and the stock price depends on consistent execution, end-market procedure volumes, and successful customer program launches.

Quick verdict table

Dimension	Conclusion	Confidence
Business quality	Integer provides medical device contract development and manufacturing with strong positions in cardiac rhythm management, neuromodulation, and structural heart components. Multi-year supply agreements create recurring revenue.	Medium-high
Moat	Moat comes from regulatory barriers (FDA validation for component manufacturing), manufacturing scale, proprietary battery and feedthrough technology for implantable devices, and long-term OEM customer relationships.	Medium
Management	Management has executed well on organic growth and strategic acquisitions. Capital allocation includes both reinvestment and debt management. Succession stability and margin improvement targets are key monitoring items.	Medium
Financial trend	TTM revenue of about $1.86 billion, net income of about $141.8 million, and levered free cash flow of about $98.1 million. Revenue has grown at a mid-single-digit pace with periodic acquisition boosts.	Medium-high
Valuation	The stock trades near 23.5x TTM earnings, 20x forward earnings, 1.8x sales, and 32.7x TTM free cash flow. EV/EBITDA of about 13.9x reflects the debt in the enterprise value. Valuation is reasonable for a niche medtech supplier with growth optionality.	Medium
Technical trend	ITGR has recovered from its 52-week low near $62 but remains well below its 52-week high near $123. The stock is in a recovery trend but faces resistance from the simple moving averages.	Medium
Risk level	Key risks are balance sheet leverage (D/E 81%, net debt to EBITDA elevated), customer concentration, OEM consolidation, medical procedure volume cyclicality, raw material costs, and regulatory changes.	Medium-high
AI confidence	Medium-high confidence for the business model, financial filings, market cap math, and major risk categories. Lower confidence for precise future returns and timing.	Medium-high data confidence
Investment certainty	Medium-low certainty. Integer has a defensible niche and reasonable valuation, but the debt load and modest profit margins limit the margin of safety.	Medium-low

ITGR AI stock forecast

ITGR AI Stock Forecast Scenarios

The ITGR AI stock forecast uses scenario ranges around the $94.57 cutoff price. It does not claim that AI can predict a specific future price. The bullish case requires sustained organic growth, successful customer program ramps, margin improvement, and debt reduction. The base case assumes Integer compounds earnings at a mid-single-digit pace with modest multiple expansion. The bearish case assumes growth disappoints, margins contract, or leverage concerns weigh on the multiple.

Bullish case

$135 to $175

More likely if Integer sustains high-single-digit organic revenue growth, expands gross margins through operating leverage and mix, reduces net leverage, and earns a multiple near 25 to 28x three-year forward EPS.

Base case

$90 to $115

More likely if Integer delivers mid-single-digit revenue growth, maintains current margins, gradually reduces debt, and the stock trades in line with its forward P/E range of 18 to 22x.

Bearish case

$55 to $80

More likely if medical procedure volumes decline, customer concentration becomes a headwind, Integer loses a major manufacturing program, or the market assigns a lower multiple due to leverage concerns.

ITGR AI technical analysis

ITGR AI Technical Analysis

ITGR AI technical analysis starts from the $94.57 close used for this July 12 static page. The stock has recovered significantly from the 52-week low near $62 but remains below the 52-week high near $123. Public technical sources showed the stock building a recovery base with improving momentum. Because this page does not fetch request-time market data, traders should confirm levels on a live chart before acting.

Level	Value	Why it matters
Current price	$94.57	Latest verified close used for this page as of the July 12, 2026 data cutoff.
Near support	$84 to $88	Support planning zone around recent consolidation levels and the rising 50-day moving average area reported by public technical sources.
Secondary support	$72 to $76	The area around prior breakout levels and potential 200-day moving average zone. A sustained break below would weaken the recovery setup.
Near resistance	$98 to $102	The round-number zone and potential 50-day or 100-day moving average resistance area. Breakout attempts need volume confirmation.
Major resistance	$115 to $123	The 52-week high and prior distribution zone. A sustained break above this area would signal a stronger trend shift.
50-day moving average	About $85 to $90	Public technical sources indicated ITGR was trading near or slightly above the 50-day moving average, a constructive near-term signal.
200-day moving average	About $95 to $100	The 200-day moving average likely sits above the current price, meaning the long-term trend is not yet confirmed as bullish.
Momentum	RSI near 55 to 60, improving	RSI was in neutral-to-modestly-bullish territory. Short-term momentum oscillators showed improvement but not overbought conditions.
Volume	About 305,000 to 525,000 shares	The July 1 volume snapshot was below the average volume, so a breakout should be confirmed by higher participation.
Volatility	ATR 14 near $3.50 to $4.50	Position sizing should allow for normal daily movement of 3% to 5% around the cutoff price.
Invalidation	Close below $84, then $72	A close below the near-support zone weakens the recovery setup. A break below secondary support would challenge the trend.

ITGR AI trading strategy

ITGR AI Trading Strategy Framework

The ITGR AI trading strategy is a rules-based framework, not personalized advice. It combines filing-backed business evidence, technical confirmation, position sizing, and clear invalidation levels.

Trend-following setup

Look for ITGR to reclaim and hold above its 200-day moving average near $95 to $100 on improving volume before treating the recovery trend as confirmed.

A failed test of the 200-day area or a daily close below $84 should reduce confidence in the recovery setup.

Mean-reversion setup

If ITGR pulls back toward $84 to $88 without breaking the recovery thesis, evaluate the next earnings catalysts, medical procedure volume trends, and debt reduction progress before considering entry.

Define maximum loss per position. Do not buy solely because the stock is cheap on P/E.

Fundamental monitor

Track quarterly revenue growth by segment, gross margin trends, debt paydown progress, free cash flow conversion, and customer program wins or losses.

Lower the rating if revenue growth decelerates, margins compress, or net leverage increases above current levels.

Investment research summary

Four-master Research Compression

Business essence

Integer manufactures critical components and finished devices for medical device OEMs, including implantable pacemaker batteries, defibrillator components, neurostimulation devices, and catheters used in structural heart and vascular procedures.

Moat

Integer benefits from regulatory barriers (OEMs cannot easily requalify a component supplier), proprietary battery and feedthrough technology for implantable devices, global manufacturing scale, and long-term supply agreements with major medtech customers.

Munger risk inversion

The thesis can fail if medtech OEMs consolidate and reduce supplier count, a key manufacturing program is lost, medical procedure volumes decline cyclically, raw material costs rise, or the debt load becomes restrictive in a rising rate environment.

Management

CEO Joseph Dziedzic and the leadership team have focused on organic growth, strategic acquisitions, and operational improvement. Debt management and consistent margin execution remain key credibility factors.

Industry trend

Integer operates in the medical device outsourcing market, which benefits from long-term secular trends in aging populations, minimally invasive procedures, and OEM preference for specialized contract manufacturers over in-house production.

Valuation and margin of safety

At roughly 23.5x TTM earnings and 20x forward earnings, the valuation is reasonable for a niche supplier with growth potential. However, the 81% debt-to-equity ratio and EV/EBITDA around 13.9x mean the enterprise is priced with leverage built in.

Source-backed data

ITGR Data Table

Every metric below includes a source and last verification date.

Metric	Value	Source	Last verified
ITGR price	$94.57 close on July 1, 2026	Yahoo Finance quote snapshot	July 12, 2026
Market capitalization	$3.21 billion, verified as $94.57 x 33,950,000 shares	financial_rigor.py market cap verification and Yahoo Finance	July 12, 2026
Enterprise value	$4.55 billion	Yahoo Finance key statistics	July 12, 2026
TTM revenue	$1.86 billion	Yahoo Finance key statistics	July 12, 2026
TTM net income	$141.8 million	Yahoo Finance key statistics	July 12, 2026
Levered free cash flow	$98.1 million	Yahoo Finance key statistics	July 12, 2026
Cash and equivalents	$8.1 million	Yahoo Finance key statistics	July 12, 2026
Total debt / equity	81.41%	Yahoo Finance key statistics	July 12, 2026
Valuation math	23.47x TTM PE, 32.72x P/FCF, 1.87x PB, 1.80x PS, 13.94x EV/EBITDA from financial_rigor.py	financial_rigor.py valuation verification and Yahoo Finance	July 12, 2026
Moving averages and momentum	50-day MA about $85 to $90, 200-day MA about $95 to $100, RSI improving near 55 to 60	Public technical chart sources	July 12, 2026

Frequently Asked Questions

Read the NVDA AI stock analysis View MMSI AI stock analysis Explore AI Stock Picker Generate an AI trading strategy

This ITGR AI stock analysis is an informational tool for research and education only. It is not investment advice, a recommendation, or a guarantee of future performance. Forecast ranges are scenarios based on available data as of July 12, 2026 and can be wrong.